Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)

On May 5, 2026, Exelixis management reiterated full-year 2026 financial guidance. Weeks later, the Company lowered and narrowed that revenue outlook -- and the stock fell. NEW YORK , Aug. 10, 2026 /PRNewswire/ -- Exelixis, Inc. (NASDAQ: EXEL ) reiterated its full-year 2026 financial guidance on its May 5, 2026 earnings call. Following its second quarter results, the Company lowered and narrowed that same revenue outlook, and shares declined. If you lost money on EXEL, you are encouraged to submit your loss information now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. On the May 5, 2026 call, Chief Financial Officer Christopher Senner stated: "Finally, we are reiterating our full year 2026 financial guidance, which is detailed on slide 16 of our earnings presentation." Chief Executive Officer Michael Morrissey told investors Exelixis was "off to a strong start in 2026" and that CABOMETYX "continued to grow in revenue, demand, and market share as the leading TKI for RCC and the market leader for neuroendocrine tumors in the oral second-line plus segment." When the Company subsequently reduced its full-year 2026 revenue guidance, it attributed the change to a slower-than-expected ramp in its neuroendocrine-tumor business. Quarterly revenue of approximately $628.7 million came in below Wall Street consensus. The investigation concerns when management first identified the slower ramp relative to the date guidance was reiterated. Shareholders who purchased EXEL and suffered losses may have their claims evaluated at no cost or call (212) 363-7500.